HUE051535T2 - Kristályos (8S,9R)-5-Fluor-8-(4-fluorfenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)-8,9-dihidro-2H- pirido[4,3,2-DE]ftalazin-3(7H)-on-tozilát-só - Google Patents
Kristályos (8S,9R)-5-Fluor-8-(4-fluorfenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)-8,9-dihidro-2H- pirido[4,3,2-DE]ftalazin-3(7H)-on-tozilát-sóInfo
- Publication number
- HUE051535T2 HUE051535T2 HUE11777005A HUE11777005A HUE051535T2 HU E051535 T2 HUE051535 T2 HU E051535T2 HU E11777005 A HUE11777005 A HU E11777005A HU E11777005 A HUE11777005 A HU E11777005A HU E051535 T2 HUE051535 T2 HU E051535T2
- Authority
- HU
- Hungary
- Prior art keywords
- phtalazin
- crystaline
- pyrido
- triazol
- fluorophenyl
- Prior art date
Links
- 125000005490 tosylate group Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40547610P | 2010-10-21 | 2010-10-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE051535T2 true HUE051535T2 (hu) | 2021-03-01 |
Family
ID=44903424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11777005A HUE051535T2 (hu) | 2010-10-21 | 2011-10-20 | Kristályos (8S,9R)-5-Fluor-8-(4-fluorfenil)-9-(1-metil-1H-1,2,4-triazol-5-IL)-8,9-dihidro-2H- pirido[4,3,2-DE]ftalazin-3(7H)-on-tozilát-só |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8735392B2 (enExample) |
| EP (2) | EP2630146B1 (enExample) |
| JP (6) | JP2013540158A (enExample) |
| KR (4) | KR20140009181A (enExample) |
| CN (1) | CN103282365B (enExample) |
| AR (1) | AR083502A1 (enExample) |
| AU (2) | AU2011317040B2 (enExample) |
| BR (1) | BR112013009117A2 (enExample) |
| CA (1) | CA2814581C (enExample) |
| CY (1) | CY1123356T1 (enExample) |
| DK (1) | DK2630146T3 (enExample) |
| ES (1) | ES2816600T3 (enExample) |
| HU (1) | HUE051535T2 (enExample) |
| IL (2) | IL225789B (enExample) |
| MX (1) | MX362563B (enExample) |
| NZ (1) | NZ609490A (enExample) |
| PL (1) | PL2630146T3 (enExample) |
| PT (1) | PT2630146T (enExample) |
| RU (1) | RU2598606C3 (enExample) |
| SG (2) | SG10201710578TA (enExample) |
| SI (1) | SI2630146T1 (enExample) |
| TW (2) | TWI557123B (enExample) |
| WO (1) | WO2012054698A1 (enExample) |
| ZA (1) | ZA201302810B (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| CN102985557B (zh) | 2009-03-13 | 2018-06-15 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| PE20120693A1 (es) | 2009-06-29 | 2012-07-04 | Agios Pharmaceuticals Inc | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| MX340319B (es) * | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| CN103282365B (zh) | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 |
| PT3406251T (pt) | 2011-05-03 | 2024-01-24 | Agios Pharmaceuticals Inc | Ativadores da piruvato-cinase para utilização em terapia |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013021044A1 (de) * | 2011-08-11 | 2013-02-14 | Bayer Intellectual Property Gmbh | 1,2,4-triazolyl-substituierte ketoenole |
| WO2013028495A1 (en) * | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| WO2014062511A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015010297A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015123424A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| LT3105218T (lt) | 2014-02-13 | 2019-12-10 | Incyte Corp | Ciklopropilaminai kaip lsd1 inhibitoriai |
| PH12021551647A1 (en) * | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| SMT202100444T1 (it) * | 2014-03-14 | 2021-09-14 | Les Laboratories Servier Sas | Composizioni farmaceutiche di composti terapeuticamente attivi |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| EA201790290A1 (ru) * | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
| EA201792205A1 (ru) | 2015-04-03 | 2018-02-28 | Инсайт Корпорейшн | Гетероциклические соединения как ингибиторы lsd1 |
| MX384883B (es) | 2015-06-11 | 2025-03-14 | Agios Pharmaceuticals Inc | Métodos para usar activadores de piruvato cinasa. |
| DK3334709T3 (da) | 2015-08-12 | 2025-02-03 | Incyte Holdings Corp | Salte af en lsd1-hæmmer |
| HUE067449T2 (hu) | 2015-10-15 | 2024-10-28 | Servier Lab | Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére |
| MD3362066T2 (ro) | 2015-10-15 | 2022-08-31 | Les Laboratoires Servier Sas | Terapie combinată pentru tratamentul tumorilor maligne |
| CN108883115A (zh) * | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| PL4049660T3 (pl) | 2016-02-29 | 2025-06-09 | F. Hoffmann-La Roche Ag | Kompozycje postaci dawkowania zawierające inhibitor kinazy tyrozynowej Brutona |
| AU2018347331A1 (en) | 2017-10-13 | 2020-04-09 | Merck Patent Gmbh | Combination of a PARP inhibitor and a PD-1 axis binding antagonist |
| TW201938165A (zh) | 2017-12-18 | 2019-10-01 | 美商輝瑞股份有限公司 | 治療癌症的方法及組合療法 |
| US11368702B2 (en) | 2018-06-04 | 2022-06-21 | Lg Electronics, Inc. | Method and device for processing video signal by using affine motion prediction |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| US10942500B2 (en) * | 2018-06-11 | 2021-03-09 | Purdue Research Foundation | System architecture and method of processing data therein |
| US10284860B1 (en) * | 2018-07-02 | 2019-05-07 | Tencent America LLC | Method and apparatus for video coding |
| CN112424671B (zh) | 2018-07-13 | 2023-10-27 | 奇跃公司 | 用于显示双目变形补偿的系统和方法 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| US20210355223A1 (en) | 2018-11-05 | 2021-11-18 | Pfizer Inc. | Combinations for Treating Cancer |
| WO2021069700A1 (en) * | 2019-10-10 | 2021-04-15 | Myovant Sciences Gmbh | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| EP4118105A2 (en) | 2020-03-09 | 2023-01-18 | Pfizer Inc. | Cd80-fc fusion protein and uses thereof |
| JP2023548896A (ja) | 2020-11-13 | 2023-11-21 | ファイザー・インク | タラゾパリブ軟質ゼラチンカプセル剤形 |
| US20240052423A1 (en) | 2020-12-07 | 2024-02-15 | Pfizer Inc. | Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof |
| EP4313034A1 (en) | 2021-03-24 | 2024-02-07 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| WO2023131894A1 (en) | 2022-01-08 | 2023-07-13 | Pfizer Inc. | Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4532493A1 (en) | 2022-06-01 | 2025-04-09 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415504A (en) | 1981-09-21 | 1983-11-15 | Tanabe Seiyaku Co., Ltd. | p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine |
| JPS58225065A (ja) | 1982-06-21 | 1983-12-27 | Nippon Shinyaku Co Ltd | ２−キノロン誘導体 |
| US5328905A (en) | 1987-07-20 | 1994-07-12 | Duphar International Research B.V. | 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives |
| GB9505538D0 (en) | 1995-03-18 | 1995-05-03 | Ciba Geigy Ag | New compounds |
| ID19155A (id) | 1996-12-13 | 1998-06-18 | Tanabe Seiyaku Co | Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya |
| DE19727410A1 (de) | 1997-06-27 | 1999-01-07 | Hoechst Schering Agrevo Gmbh | 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| TW430656B (en) | 1997-12-03 | 2001-04-21 | Dainippon Ink & Chemicals | Quinolinone derivative, method for preparing the same, and anti-allergic agent |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| DE19921567A1 (de) | 1999-05-11 | 2000-11-16 | Basf Ag | Verwendung von Phthalazine-Derivaten |
| JP2001302669A (ja) | 2000-04-18 | 2001-10-31 | Meiji Seika Kaisha Ltd | 三環性フタラジノン誘導体 |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| KR100663147B1 (ko) * | 2002-02-19 | 2007-02-28 | 오노 야꾸힝 고교 가부시키가이샤 | 축합 피리다진 유도체 화합물 및 이를 유효 성분으로서함유하는 약제 |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| AU2003277674A1 (en) | 2002-11-12 | 2004-06-03 | Mochida Pharmaceutical Co., Ltd. | Novel parp inhibitors |
| PL1633724T3 (pl) | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
| EP1633362B1 (en) | 2003-05-28 | 2012-09-26 | Eisai Inc. | Compounds, methods and pharmaceutical compositions for inhibiting parp |
| WO2005080356A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonits |
| GB0612971D0 (en) | 2006-06-30 | 2006-08-09 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US8198448B2 (en) | 2006-07-14 | 2012-06-12 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EA015952B1 (ru) | 2007-05-03 | 2011-12-30 | Пфайзер Лимитед | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов |
| WO2010017850A1 (de) | 2008-08-12 | 2010-02-18 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von cycloalkyl-substituierten piperazinverbindungen |
| BRPI0721950A2 (pt) | 2007-08-22 | 2015-09-29 | 4Sc Ag | indolopiridinas como inibidores da proteína de fuso de cinesina |
| CN101998959B (zh) | 2008-02-06 | 2013-08-28 | 生物马林药物股份有限公司 | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 |
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| US20110190266A1 (en) | 2010-02-04 | 2011-08-04 | Daniel Chu | 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) |
| MX340319B (es) | 2010-02-08 | 2016-07-06 | Medivation Technologies Inc | Procesos para sintetizar derivados de dihidropiridoftalazinona. |
| WO2011130661A1 (en) | 2010-04-16 | 2011-10-20 | Biomarin Pharmaceutical Inc. | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) |
| WO2011140009A1 (en) | 2010-05-04 | 2011-11-10 | Biomarin Pharmaceutical Inc. | Methods of using semi-synthetic glycopeptides as antibacterial agents |
| CN103282365B (zh) | 2010-10-21 | 2017-12-29 | 麦迪韦逊科技有限公司 | 结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 |
| WO2012166151A1 (en) | 2011-06-03 | 2012-12-06 | Biomarin Pharmaceutical Inc. | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) |
| WO2013028495A1 (en) | 2011-08-19 | 2013-02-28 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma |
| US20130053365A1 (en) | 2011-08-30 | 2013-02-28 | Biomarin Pharmaceutical, Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| EP3066084A1 (en) | 2013-11-07 | 2016-09-14 | Medivation Technologies, Inc. | Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes |
| EA201790290A1 (ru) | 2014-07-31 | 2017-07-31 | Медивэйшн Текнолоджиз, Инк. | Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения |
-
2011
- 2011-10-20 CN CN201180062085.0A patent/CN103282365B/zh active Active
- 2011-10-20 JP JP2013535079A patent/JP2013540158A/ja active Pending
- 2011-10-20 KR KR1020137012297A patent/KR20140009181A/ko not_active Ceased
- 2011-10-20 KR KR1020197030773A patent/KR20190120458A/ko not_active Ceased
- 2011-10-20 HU HUE11777005A patent/HUE051535T2/hu unknown
- 2011-10-20 US US13/277,607 patent/US8735392B2/en active Active
- 2011-10-20 KR KR1020217006784A patent/KR20210028747A/ko not_active Ceased
- 2011-10-20 MX MX2013004195A patent/MX362563B/es active IP Right Grant
- 2011-10-20 PL PL11777005T patent/PL2630146T3/pl unknown
- 2011-10-20 TW TW100138150A patent/TWI557123B/zh active
- 2011-10-20 PT PT117770057T patent/PT2630146T/pt unknown
- 2011-10-20 RU RU2013123036A patent/RU2598606C3/ru active Protection Beyond IP Right Term
- 2011-10-20 ES ES11777005T patent/ES2816600T3/es active Active
- 2011-10-20 EP EP11777005.7A patent/EP2630146B1/en active Active
- 2011-10-20 AU AU2011317040A patent/AU2011317040B2/en active Active
- 2011-10-20 BR BR112013009117A patent/BR112013009117A2/pt not_active Application Discontinuation
- 2011-10-20 WO PCT/US2011/057039 patent/WO2012054698A1/en not_active Ceased
- 2011-10-20 EP EP20175014.8A patent/EP3757106A1/en not_active Withdrawn
- 2011-10-20 SI SI201131903T patent/SI2630146T1/sl unknown
- 2011-10-20 SG SG10201710578TA patent/SG10201710578TA/en unknown
- 2011-10-20 AR ARP110103892A patent/AR083502A1/es not_active Application Discontinuation
- 2011-10-20 CA CA2814581A patent/CA2814581C/en active Active
- 2011-10-20 TW TW105123467A patent/TWI643858B/zh active
- 2011-10-20 SG SG2013029731A patent/SG189939A1/en unknown
- 2011-10-20 DK DK11777005.7T patent/DK2630146T3/da active
- 2011-10-20 NZ NZ609490A patent/NZ609490A/en unknown
- 2011-10-20 KR KR1020187016905A patent/KR20180069132A/ko not_active Ceased
-
2013
- 2013-04-17 IL IL225789A patent/IL225789B/en active IP Right Grant
- 2013-04-18 ZA ZA2013/02810A patent/ZA201302810B/en unknown
-
2014
- 2014-04-14 US US14/252,668 patent/US20140228369A1/en not_active Abandoned
-
2016
- 2016-11-18 JP JP2016224670A patent/JP2017061526A/ja active Pending
-
2017
- 2017-03-07 AU AU2017201564A patent/AU2017201564B2/en active Active
- 2017-07-17 US US15/651,735 patent/US10189837B2/en active Active
-
2018
- 2018-10-11 JP JP2018192521A patent/JP2019034951A/ja not_active Withdrawn
-
2019
- 2019-12-17 IL IL271497A patent/IL271497A/en unknown
-
2020
- 2020-07-09 JP JP2020118281A patent/JP2020169209A/ja not_active Withdrawn
- 2020-09-22 CY CY20201100893T patent/CY1123356T1/el unknown
-
2022
- 2022-08-02 JP JP2022123448A patent/JP2022140637A/ja not_active Withdrawn
-
2024
- 2024-08-07 JP JP2024130494A patent/JP2024150772A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL271497A (en) | Tosylate salt of (S8, R9)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-H1- 4,2,1-triazol-5-yl)-9,8-dihydro-H2 -Crystalline pyrido[2,3,4-de]phthalazine-3(H3)-one | |
| EP2656847A4 (en) | CONJUGATE FOR PHOTODYNAMIC DIAGNOSIS OR THERAPY AND PREPARATION METHOD THEREOF | |
| ZA201209632B (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| SI2477648T1 (sl) | Sinergijska terapija proti CD47 za krvne rake | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| ZA201302271B (en) | Controlled motorized brewing unit | |
| EP2619203A4 (en) | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF | |
| IL218490A0 (en) | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | |
| PL2616065T3 (pl) | GLIKO-PODSTAWIONE DIHYDROKSYCHLORYNY I ß-FUNKCJONALIZOWANE CHLORYNY DO PRZECIWDROBNOUSTROJOWEJ TERAPII FOTODYNAMICZNEJ | |
| EP2552833A4 (en) | Surface-modified zeolites and methods for preparing the same | |
| IL229993A (en) | 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2 | |
| IL221479A0 (en) | Triazolo [4,5-b] pyridin derivatives | |
| IL220448A (en) | Pyridine [3,2 - d] Pyrimidine - 7 (8h) - Their medical uses and uses | |
| IL226228A0 (en) | derivation of pyrazino[3,2–d]isooxazole | |
| HK1188783B (en) | Crystaline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phtalazin-3(7h)-one tosylate salt | |
| IL236808B (en) | Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one | |
| PL2477990T3 (pl) | Pochodne 5-fenylopirazolopirydyny, ich wytwarzanie oraz ich zastosowanie terapeutyczne | |
| EP2651937B8 (en) | Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy | |
| IL226054A0 (en) | Oxazolo[4,5-b]pyridin-5-yl compounds and their use in cancer treatment | |
| EP2621490A4 (en) | PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | |
| HK1188783A (zh) | 結晶的(8s，9r)-5-氟-8-(4-氟苯基)-9-(1-甲基-1h-1，2，4-三唑-5-基)-8，9-二氫-2h-吡啶並[4，3，2-de]酞嗪-3(7h)-酮甲苯磺酸鹽 | |
| IL226388A0 (en) | New indolizine derivatives, their preparation and medical use | |
| HK1179251A (en) | Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof | |
| HK1186470A (en) | Oxazolo [5, 4 -b]pyridin- 5 -yl compounds and their use for the treatment of cancer | |
| AU2010902149A0 (en) | Safe drink detector |